At this year’s American College of Cardiology Scientific Sessions in Chicago, USA (29-31 March 2025), Lp(a) research highlights included results of the Phase 2 ALPACA trial of lepodisiran, the impact of Lp(a) testing on cardiovascular (CV) event reduction, and reasons why testing is not more widespread. In addition, researchers presented data showing the importance of […]
In the Phase 2 ALPACA study, Lp(a) levels were reduced from baseline by up to 93.9% compared to placebo, from day 60 to 180, after a single dose of the investigational siRNA, lepodisiran.1 Sustained reductions of up to 53.4% were recorded at 540 days after a single dose and 74.2% at 540 days following a […]
Further evidence that Lp(a) testing helps boost initiation and intensification of lipid lowering therapy (LLT), with lower LDL-C and fewer cardiovascular (CV) events, comes from a large pooled analysis of the effects of Lp(a) testing in patients with atherosclerotic cardiovascular disease (ASCVD).
Elevated Lp(a) levels are associated with an increased risk of proliferative diabetic retinopathy (PDR) and may be a useful screening tool for this complication in patients with diabetes. This is the conclusion of researchers who assessed the association between Lp(a) and diabetic retinopathy (DR) subtypes (non-proliferative, proliferative, and diabetic macular oedema) in a sample of […]
Growing evidence is linking Lp(a) to the presence of plaque, but the association is not always straightforward, as demonstrated by presentations at ACC.25. In a sub analysis of data from the GLOBAL study of cardiac CT in suspected coronary artery disease (CAD), Lp(a) was associated with the presence of plaque, especially high risk, partially calcified […]
The top four reasons why clinicians do not test Lp(a) are a lack of specific guidelines on how to manage patients with raised levels, a lack of harmonised guidelines on who should be tested, a lack of approved Lp(a) lowering treatments, and a lack of awareness about the importance of Lp(a) as a risk factor.
